$3.27
+0.14 (+4.47%)
Open$3.07
Previous Close$3.13
Day High$3.29
Day Low$3.07
52W High$5.55
52W Low$2.94
Volume—
Avg Volume508.7K
Market Cap189.12M
P/E Ratio—
EPS$-1.98
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+1,320.2% upside
Current
$3.27
$3.27
Target
$46.44
$46.44
$29.94
$46.44 avg
$64.67
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 42.94M | 43.12M | 42.57M |
| Net Income | -127,314,891 | -115,078,238 | -129,666 |
| Profit Margin | -296.5% | -281.7% | -0.3% |
| EBITDA | -135,890,764 | -129,653,736 | -158,434 |
| Free Cash Flow | — | — | -114,389 |
| Rev Growth | -0.4% | -0.4% | +21.1% |
| Debt/Equity | — | — | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |